Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines
- 1 August 1984
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 27 (8) , 1077-1083
- https://doi.org/10.1021/jm00374a024
Abstract
The hypothesis that the side effects of hydralazine, such as mutagenicity and lupus erythematosus like syndrome, might be due to the NHNH2 group prompted the decision to incorporate this moiety into a pyrrole ring. Therefore, a series of N-1H-pyrrol-1-yl-3-pyridazinamines and a limited number of N-1H-pyrrol-1-yl-1-phthalazinamines were prepared by reaction of 3-hydrazinopyridazines and 1-hydrazinophthalazines with .gamma.-diketones. Most of these compounds, especially in the pyridazine series, showed moderate to strong antihypertensive activity in spontaneously hypertensive rats. The decrease in blood pressure generally had a slow onset after either oral or i.v. administration. N-(2,5-Dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (30) (MDL 899) showed no mutagenic activity in several tests and is now in clinical trials in patients.This publication has 3 references indexed in Scilit:
- Genetic effects of hydralazineMutation Research/Genetic Toxicology, 1979
- Synthesis and Properties of Mesoionic Pyrimido[1,2‐b]pyridazine‐2,4‐diones and Mesoionic Pyridazino[2,3‐a]‐s‐triazine‐2,4‐diones: Mesoionic Analogs Structurally Related to FervenulinJournal of Pharmaceutical Sciences, 1976
- STUDIES ON EXPERIMENTAL HYPERTENSIONThe Journal of Experimental Medicine, 1934